(Q33439705)

English

Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5905335

Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers (English)

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5905335

phase I clinical trial

0 references

object named as

David C Smith

10

0 references

9

object named as

John Heymach

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5905335

1

object named as

Johann de Bono

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5905335

author name string

Ramesh K Ramanathan

2

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5905335

Lida Mina

3

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5905335

Rashmi Chugh

4

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5905335

John Glaspy

5

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5905335

Saeed Rafii

6

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5905335

Stan Kaye

7

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5905335

Jasgit Sachdev

8

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5905335

Joshua W Henshaw

11

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5905335

Ashleigh Herriott

12

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5905335

Miranda Patterson

13

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5905335

Nicola J Curtin

14

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5905335

Lauren Averett Byers

15

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5905335

Zev A Wainberg

16

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5905335

language of work or name

0 references

publication date

27 February 2017

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5905335

Cancer Discovery

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5905335

7

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5905335

6

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5905335

620-629

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5905335

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5905335

21 June 2018

Whole genomes redefine the mutational landscape of pancreatic cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5905335

21 June 2018

Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5905335

21 June 2018

Structural basis for the inhibition of poly(ADP-ribose) polymerases 1 and 2 by BMN 673, a potent inhibitor derived from dihydropyridophthalazinone

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5905335

21 June 2018

Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5905335

21 June 2018

PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5905335

21 June 2018

Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5905335

21 June 2018

Combining PARP-1 inhibition and radiation in Ewing sarcoma results in lethal DNA damage

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5905335

21 June 2018

Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5905335

21 June 2018

The diverse roles and clinical relevance of PARPs in DNA damage repair: current state of the art.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5905335

21 June 2018

Systematic identification of genomic markers of drug sensitivity in cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5905335

21 June 2018

Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5905335

21 June 2018

PARP inhibition: PARP1 and beyond

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5905335

21 June 2018

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5905335

21 June 2018

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5905335

21 June 2018

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5905335

21 June 2018

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5905335

21 June 2018

Poly(ADP-ribose) polymerase-1: what have we learned from the deficient mouse model?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5905335

21 June 2018

PARP-2, A novel mammalian DNA damage-dependent poly(ADP-ribose) polymerase

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5905335

21 June 2018

Involvement of poly(ADP-ribose) polymerase in base excision repair

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5905335

21 June 2018

Role of poly(ADP-ribose) formation in DNA repair

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5905335

21 June 2018

BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5905335

31 October 2018

Phase II trial to evaluate gemcitabine and etoposide for locally advanced or metastatic pancreatic cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5905335

31 October 2018

Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5905335

31 October 2018

Accelerated titration designs for phase I clinical trials in oncology

1 reference

https://pubmed.ncbi.nlm.nih.gov/28242752

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1158/2159-8290.CD-16-1250

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5905335

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5905335

1 reference

Europe PubMed Central

15 June 2018

http://europepmc.org/abstract/PMC/5905335

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33439705&oldid=1869086818"